Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide

Journal of Experimental Medicine

Volumn 188, Issue 3, 1998, Pages 431-438

  Bradt, Bonnie M ^a   Kolb, William P ^b   Cooper, Neil R ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Advanced Research Technology   (United States)

^c 10550 North Torrey Pines Rd ^*  (United States)

Author keywords

Alzheimer's disease; Amyloid; C3; Complement; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CELL MEMBRANE PERMEABILITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFLAMMATION; MICROGLIA; NEOCORTEX; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; COMPLEMENT C3; COMPLEMENT C3B; COMPLEMENT C5; COMPLEMENT C5A; COMPLEMENT C5B; HUMANS; PEPTIDE FRAGMENTS; RABBITS;

EID: 0032479929     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.3.431     Document Type: Article

References (35)

1. Eikelenboom, P., and F.C. Stam. 1982. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 57:239-242.
2. McGeer, P.L., and E.G. McGeer. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21:195-218.
3. Rogers, J., N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, P. Ward, and I. Lieberburg. 1992. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 89:10016-10020.
4. Müller-Eberhard, H.J. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57: 321-347.
5. Cooper, N.R. 1998. Biology of the complement system. In Inflammation: Basic Principles and Clinical Correlates. J. Gallin and R. Snyderman, editors. Lippincott-Raven Publishers, Philadelphia. In press.
6. Morgan, B.P., and P. Gasque. 1996. Expression of complement in the brain: role in health and disease. Immunol. Today. 17:461-466.
7. Jiang, H., D. Burdick, C.G. Glabe, C.W. Cotman, and A.J. Tenner. 1994. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:5050-5059.
8. Chen, S., R.C.A. Frederickson, and K.R. Brunden. 1996. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol. Aging. 17:781-787.
9. Webster, S., B. Bradt, J. Rogers, and N.R. Cooper. 1997. Aggregation state-dependent activation of the classical complement pathway by the amyloid β peptide (Aβ). J. Neurochem. 69:388-398.
10. Cadman, E.D., and P.S. Puttfarcken. 1997. β-Amyloid peptides initiate the complement cascade without producing a comparable effect on the terminal pathway in vitro. Exp. Neurol. 146:388-394.
11. Webster, S., B. Bonnell, and J. Rogers. 1997. Charge-based binding of complement component C1q to the Alzheimer amyloid β-peptide. Am. J. Pathol. 150:1531-1536.
12. Velazquez, P., D.H. Cribbs, T.L. Poulos, and A.J. Tenner. 1997. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3:77-79.
13. Schreiber, R.D., M.K. Pangburn, P.H. Lesavre, and H.J. Müller-Eberhard. 1978. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. USA. 75:3948-3952.
14. 5 promote adenovirus internalization but not virus attachment. Cell. 73:309-319.
15. Mayer, M.M. 1961. Complement and complement fixation. In Experimental Immunochemistry. E.A. Kabat and M.M. Mayer, editors. Charles C. Thomas Publisher, Springfield, IL. 133-241.
16. Wagner, J.L., and T.E. Hugli. 1984. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal. Biochem. 136:75-88.
17. McGeer P.L., H. Akiyama, S. Itagaki, and E.G. McGeer. 1989. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527.
18. McGeer, P.L., H. Akiyama, S. Itagaki, and E.G. McGeer. 1989. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:341-346.
19. Law, S.K.A., N.A. Lichtenberg, and R.P. Levine. 1979. Evidence for an ester linkage between the labile binding sue of C3b and receptive surfaces. J. Immunol. 123:1388-1394.
20. Gadd, K.J., and K.B.M. Reid. 1981. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem. J. 195:471-480.
21. Miller, G.W., and V. Nussenzweig. 1975. A new complement function: solubilization of antigen-antibody aggregates. Proc. Natl. Acad. Sci. USA. 72:418-422.
22. Fujita, T., Y. Takata, and N. Tamura. 1981. Solubilization of immune precipitates by six isolated alternative pathway proteins. J. Exp. Med. 154:1743-1751.
23. Harris, M.E., K. Hensley, D.A. Butterfield, R.A. Leedle, and J.M. Carney. 1995. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:193-202.
24. Dyrks, T., E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther. 1992. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:18210-18217.
25. Hensley, K., D.A. Butterfield, N. Hall, P. Cole, R. Subramanian, R. Mark, M.P. Mattson, W.K. Markesbery, M.E. Harris, M. Aksenov, et al. 1996. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Ann. NY Acad. Sci. 786: 120-134.
26. Hugh, T.E. 1984. Structure and function of the anaphylatoxins. Springer Semin. Immunopathol. 7:193-219.
27. Shen, Y., J.A. Halperin, and C.-M. Lee. 1995. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:282-292.
28. Griffin, W.S.T., J.G. Sheng, G.W. Roberts, and R.E. Mrak. 1995. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:276-281.
29. Yao, J., L. Harvath, D.L. Gilbert, and C.A. Colton. 1990. Chemotaxis by CNS macrophage, the microglia. J. Neurosci. Res. 27-36-42.
30. Lacy, M., J. Jones, S.R. Whittemore, D.L. Haviland, R.A. Wetsel, and S.R. Barnum. 1995. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J. Neuroimmunol. 61:71-78.
31. Ilschner, S., C. Nolte, and H. Kettenmann. 1996. Complement factor C5a and epidermal growth factor trigger the activation of outward potassium currents in cultured murine microglia. Neuroscience. 73:1109-1120.
32. Benveniste, E.N. 1992. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am. J. Physiol. 263:C1-C16.
33. Selkoe, D.J. 1994. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53:438-447.
34. Vedeler, C., E. Ulvestad, L. Bjorge, G. Conti, K. Williams, S. Mork, and R. Matre. 1994. The expression of CD59 in normal human nervous tissue. Immunology. 82:542-547.
35. Rus, H.G., F. Niculescu, and M.L. Shin. 1996. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156:4892-4900.